Updated Canadian Headache Society Migraine Prevention Guideline with Systematic Review and Meta-analysis

被引:1
作者
Medrea, Ioana [1 ,3 ]
Cooper, Paul [2 ]
Langman, Marissa [2 ]
Sandoe, Claire H. [3 ]
Amoozegar, Farnaz [4 ]
Hussain, Wasif M. [5 ]
Bradi, Ana C. [6 ]
Dawe, Jessica [7 ]
Guay, Meagan [8 ]
Perreault, Francois [9 ]
Reid, Stuart [10 ]
Todd, Candice [3 ]
Skidmore, Becky
Christie, Suzanne N. [6 ]
机构
[1] SUNY Upstate Med Univ, Syracuse, NY USA
[2] Univ Western Ontario, Bowmanville, ON, Canada
[3] Univ Toronto, Toronto, ON, Canada
[4] Univ Calgary, South Hlth Campus, Calgary, AB, Canada
[5] Univ Alberta, Div Neurol, Kaye Edmonton Clin, Edmonton, AB, Canada
[6] Univ Ottawa, Ottawa, ON, Canada
[7] Dalhousie Univ, Dalhousie, NB, Canada
[8] McMaster Univ, Mississauga, ON, Canada
[9] Univ Montreal, Div Neurol, CHUM, Montreal, PQ, Canada
[10] Queens Univ, Queens Univ Lib, Kingston, ON, Canada
关键词
Migraine; headache; migraine research; guideline; QUALITY-OF-LIFE; PLACEBO-CONTROLLED PHASE; DOUBLE-BLIND; EPISODIC MIGRAINE; PROPHYLACTIC TREATMENT; ONABOTULINUMTOXINA TREATMENT; SODIUM VALPROATE; CONTROLLED-TRIAL; CLINICAL-TRIALS; REAL-WORLD;
D O I
10.1017/cjn.2024.285
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: We have updated the migraine prevention guideline of the Canadian Headache Society from 2012, as there are new therapies available, and additionally, we have provided guidelines for the prevention of chronic migraine, which was not addressed in the previous iteration. Methods: We undertook a systematic review to identify new studies since the last guideline. For studies identified, we performed data extraction and subsequent meta-analyses where possible. We composed a summary of the evidence found and undertook a modified Delphi recommendation process. We provide recommendations for treatments identified and additionally expert guidance on the use of the treatments available in important clinical situations. Results: We identified 61 studies that were included in this evidence update and identified 16 therapies we focused on. The anti-calcitonin gene-related peptide (CGRP) agents were approved by Health Canada between 2018 and 2024 and provide additional options for episodic and chronic migraine prevention. We also summarize evidence for the use of propranolol, topiramate and onabotulinumtoxinA in addition to anti-CGRP agents as treatments for chronic migraine. We have downgraded topiramate to a weak recommendation for use and gabapentin to a weak recommendation against its use in episodic migraine. We have weakly recommended the use of memantine, levetiracetam, enalapril and melatonin in episodic migraine. Conclusion: Based on the evidence synthesis, we provide updated recommendations for the prevention of episodic and chronic migraine utilizing treatments available in Canada. We additionally provided expert guidance on their use in clinical situations.
引用
收藏
页码:450 / 472
页数:23
相关论文
共 157 条
  • [21] Simvastatin and Vitamin D for Migraine Prevention: A Randomized, Controlled Trial
    Buettner, Catherine
    Nir, Rony-Reuven
    Bertisch, Suzanne M.
    Bernstein, Carolyn
    Schain, Aaron
    Mittleman, Murray A.
    Burstein, Rami
    [J]. ANNALS OF NEUROLOGY, 2015, 78 (06) : 970 - 981
  • [22] Burch Rebecca, 2021, Continuum (Minneap Minn), V27, P613, DOI 10.1212/CON.0000000000000957
  • [23] Epidemiology and Treatment of Menstrual Migraine and Migraine During Pregnancy and Lactation: A Narrative Review
    Burch, Rebecca
    [J]. HEADACHE, 2020, 60 (01): : 200 - 216
  • [24] Chronic Migraine Prevalence, Disability, and Sociodemographic Factors: Results From the American Migraine Prevalence and Prevention Study
    Buse, Dawn C.
    Manack, Aubrey N.
    Fanning, Kristina M.
    Serrano, Daniel
    Reed, Michael L.
    Turkel, Catherine C.
    Lipton, Richard B.
    [J]. HEADACHE, 2012, 52 (10): : 1456 - 1470
  • [25] Nonclinical safety evaluation of erenumab, a CGRP receptor inhibitor for the prevention of migraine
    Bussiere, Jeanine L.
    Davies, Rhian
    Dean, Charles
    Xu, Cen
    Kim, Kyung Hoon
    Vargas, Hugo M.
    Chellman, Gary J.
    Balasubramanian, Ganesh
    Rubio-Beltran, Eloisa
    MaassenVanDenBrink, Antoinette
    Monticello, Thomas M.
    [J]. REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2019, 106 : 224 - 238
  • [26] cadth, CADTH Recommendation ATOGEPANT
  • [27] Comparison of 3 Treatment Strategies for Medication Overuse Headache A Randomized Clinical Trial
    Carlsen, Louise Ninett
    Munksgaard, Signe Bruun
    Nielsen, Mia
    Engelstoft, Ida Maria Storm
    Westergaard, Maria Lurenda
    Bendtsen, Lars
    Jensen, Rigmor Hojland
    [J]. JAMA NEUROLOGY, 2020, 77 (09) : 1069 - 1078
  • [28] Proposed new diagnostic criteria for chronic migraine
    Chalmer, Mona Ameri
    Hansen, Thomas Folkmann
    Lebedeva, Elena R.
    Dodick, David W.
    Lipton, Richard B.
    Olesen, Jes
    [J]. CEPHALALGIA, 2020, 40 (04) : 399 - 406
  • [29] Blood pressure elevation in erenumab-treated patients with migraine: A retrospective real-world experience
    Chhabra, Nikita
    Mead-Harvey, Carolyn
    Dodoo, Christopher A.
    Iser, Courtney
    Taylor, Hallie
    Chaudhary, Hira
    Vanood, Aimen
    Dodick, David W.
    [J]. HEADACHE, 2024, 64 (03): : 233 - 242
  • [30] TOP-PRO study: A randomized double-blind controlled trial of topiramate versus propranolol for prevention of chronic migraine
    Chowdhury, Debashish
    Bansal, Luv
    Duggal, Ashish
    Datta, Debabrata
    Mundra, Ankit
    Krishnan, Anand
    Koul, Arun
    Gupta, Anu
    [J]. CEPHALALGIA, 2022, 42 (4-5) : 396 - 408